PT  - JOURNAL ARTICLE
AU  - Gambitta, L
AU  - Campbell Davies, S
AU  - Galfrascoli, E
AU  - Calzavara, E
AU  - Curci, V
TI  - 4CPS-032 Antibiotic prescription through motivated request: clinical pharmacy tool to improve appropriateness and limit resistant bacterial strains. A follow-up after a year of monitoring in a local hospital
AID  - 10.1136/ejhpharm-2020-eahpconf.133
DP  - 2020 Mar 01
TA  - European Journal of Hospital Pharmacy
PG  - A62--A62
VI  - 27
IP  - Suppl 1
4099  - http://ejhp.bmj.com/content/27/Suppl_1/A62.1.short
4100  - http://ejhp.bmj.com/content/27/Suppl_1/A62.1.full
SO  - Eur J Hosp Pharm2020 Mar 01; 27
AB  - Background and importance In Italy, antimicrobial resistance is among the highest in Europe. The ECDC 2017 surveillance report confirmed a high percentage of critical bacterial isolates with disturbing antimicrobial resistance characteristics, according to the WHO list of dangerous bacteria: Klebsiella pneumoniae resistance to carbapenems close to 28%; Escherichia coli with combined resistance (third generation cephalosporins, fluoroquinolones and aminoglycosides) close to 20%; and Acinetobacter strains resistance to carbapenems of about 70% in Italy. The hospital pharmacy plays a main role in monitoring antibiotic prescriptions in order to limit resistant bacterial strain selection.Aim and objectives To describe the pattern of antimicrobial prescribing with motivated request, comparing 2019 data with that of the previous year, to define the future strategy of the intervention.Material and methods We collected data from antibiotic prescription forms from January to June 2019. We compared data with that of same period in 2018. An Excel database was created. We focused on: length of therapy, type of infection, amount of carbapenems used, resistant bacterial strains and appropriateness of antibiotic choice according to an antibiogram.Results We collected antibiotic prescriptions for 177 (vs 148 in 2018) patients (58% men). Average age was 62 years. Average length of therapy was 8.4 days (previous year 10.5 days). Prevalent types of infection were: 12% (vs 23% in 2018) urinary tract infections (UTI), 26% (vs 22% in 2018) respiratory tract infections; 14% sepsis (same as 2018) and 13% (vs 10% in 2018) surgical site infections. Concerning critical bacterial strains: in 23% (vs 26% in 2018) of UTI, E coli ESBL+ was isolated and treated with carbapenems; only 2 (vs 5 in 2018) Klebsiella carbapenem resistant strains were found; 0 (vs 1 in the previous year) isolation of Acinetobacter baumanii multidrug resistant was found; and 2 Pseudomonas aeruginosa carbapenem resistant strains were found, which required treatment with ceftolozane/tazobactam with clinical benefit. Considering all patients, 62% (vs 54% in 2018) of patients were treated with carbapenems. Antibiograms were available for 25% (41/162) of motivated requests, and 25% (10/41) of these were inappropriate because piperacillin/tazobactam or cephalosporins should have been chosen instead of carbapenems.Conclusion and relevance Although a slight reduction in critical bacterial strains was observed compared with the previous year and an improvement in average length of therapy, carbapenems usage increased. This was also due to antibiogram misinterpretation. A future objective has to be improvement in the carbapenem sparing strategy, through clinical pharmacist validation of antibiograms and hospital training meetings.References and/or acknowledgements 1. ECDC—Antimicrobial Resistance Surveillance Report, 2017.No conflict of interest.